Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
12 mars 2020 09h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- HAIFA, Israel, March 12, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform...
Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal
03 mars 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Therapeutics CEO Issues Shareholder Update
10 févr. 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell therapy products,...
In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.
03 févr. 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study
17 déc. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment
03 déc. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Therapeutics CEO Issues Shareholder Update
12 nov. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare
04 nov. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020 HAIFA, Israel, Nov. ...
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs
16 sept. 2019 12h20 HE
|
Pluristem Therapeutics, Inc.
PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantationData from 1st and 2nd...
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs
09 sept. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced...